World Monitor Magazine WM_November_2019_web | Page 40

EXPERT OPINION
A record number of innovative medicines were launched in 2018
bringing 59 new treatment options to patients
New Actives Substances (NAS) Launched for the First Time in the United States in 2018
Therapy Area
3%
3%
3%
3%
12%
Orphan Designation
27%
12%
Predictive Biomarker
FDA First-in-Class
20%
27%
34%
49%
51%
7%
8%
Type of Molecule
73%
20%
66%
80%
N=59
Oncology
Infectious Disease
Neurology
Hematology
Endocrinology
Cardiovascular
Nephrology
Ophthalmology
Respiratory
Other
Orphan Biologics Predictive Biomarker FDA First-in-Class
Non-Orphan Non-Biologics No Predictive Biomarker Existing Mechanism
Source: IQVIA Institute, Mar 2019
7
IQVIA Russia General Managers Meeting 091819
successful webinar for doctors, preparing
information platforms for the public
and doctors to improve understanding
about the disease and the importance of
choosing the right treatment method.
At Takeda, we make decisions
according to our priorities – Patient-
Trust-Reputation-Business. First of
all, we think about how to determine
the treatment for a patient, how to
help him/her, how to ensure that he/
she has access to the therapy that he/
she needs. We achieve this through a
commitment to developing our trusted
relationships with our stakeholders. We
do care about our reputation. Here in
Kazakhstan, in the cluster, we are more
than ever committed for supporting and
developing the healthcare system. We
see the company as a partner of the
government and the medical community.
Partnership in our understanding is
the attraction of innovation and new
methods of treatment. We participate in
38
world monitor
the process of training, the development
of knowledge and skills of health
professionals while helping the entire
chain – from high-tech developments
and diagnostics to providing the drug
through pharmacies to the patient. We
widely use modern methods of Health
Technology Assessment (HTA) and here,
we work closely with KazSPOR. We were
the general sponsors and ideological
inspirers of the first HTA conference
on Central Asia in 2017, where many
experts gathered and discussed ideas,
problems and principles of introducing
HTA in Central Asia.
Over the past years, Takeda has
become one of the global leaders in
biopharmaceuticals, and we place a
great emphasis on scientific research
and cooperation with start-ups and
university bases for the development
of new treatment methods. So over the
past year, we have agreements with
the Memorial Sloan Kettering Cancer
Centre and The University of Texas MD
Anderson Cancer Centre to develop and
further commercialize new approaches
in the treatment of multiple myeloma,
acute myeloid leukemia and other
indications for blood cancer. We also
bring the practice of global colleagues
to the countries of our region. We
have concluded memorandums for
the development of joint projects with
medical universities, including the
Kazakh National Medical University
after Asfendiyarov. Besides, we work
with universities such as KBTU and
International IT University to attract
new technologies in medicine. We
participated in HackDay-2018 and
entered the KBTU Advisory Board.
On the other hand, we share know-
how with the universities of KIMEP,
UIB, AlmaU, NARXOZ about how the
processes in the company organized,
how management systems work and
accept future managers for internships
as part of our Takeda Stars programme.